Tanvex BioPharma (Taiwan) Probability of Future Stock Price Finishing Over 70.30
| 6541 Stock | TWD 70.30 2.20 3.23% |
Tanvex |
Tanvex BioPharma Target Price Odds to finish over 70.30
The tendency of Tanvex Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 70.30 | 90 days | 70.30 | about 16.05 |
Based on a normal probability distribution, the odds of Tanvex BioPharma to move above the current price in 90 days from now is about 16.05 (This Tanvex BioPharma probability density function shows the probability of Tanvex Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon Tanvex BioPharma has a beta of 0.61. This suggests as returns on the market go up, Tanvex BioPharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Tanvex BioPharma will be expected to be much smaller as well. Additionally Tanvex BioPharma has an alpha of 0.243, implying that it can generate a 0.24 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Tanvex BioPharma Price Density |
| Price |
Predictive Modules for Tanvex BioPharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Tanvex BioPharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Tanvex BioPharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Tanvex BioPharma is not an exception. The market had few large corrections towards the Tanvex BioPharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Tanvex BioPharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Tanvex BioPharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.24 | |
β | Beta against Dow Jones | 0.61 | |
σ | Overall volatility | 3.92 | |
Ir | Information ratio | 0.07 |
Tanvex BioPharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Tanvex BioPharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Tanvex BioPharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the revenue of 5.41 M. Net Loss for the year was (1.54 B) with profit before overhead, payroll, taxes, and interest of 3.55 M. | |
| Tanvex BioPharma has accumulated about 1.65 B in cash with (1.39 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.29. | |
| Roughly 54.0% of the company shares are owned by insiders or employees |
Tanvex BioPharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Tanvex Stock often depends not only on the future outlook of the current and potential Tanvex BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tanvex BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 352.5 M |
Tanvex BioPharma Technical Analysis
Tanvex BioPharma's future price can be derived by breaking down and analyzing its technical indicators over time. Tanvex Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Tanvex BioPharma. In general, you should focus on analyzing Tanvex Stock price patterns and their correlations with different microeconomic environments and drivers.
Tanvex BioPharma Predictive Forecast Models
Tanvex BioPharma's time-series forecasting models is one of many Tanvex BioPharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Tanvex BioPharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Tanvex BioPharma
Checking the ongoing alerts about Tanvex BioPharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Tanvex BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| The company reported the revenue of 5.41 M. Net Loss for the year was (1.54 B) with profit before overhead, payroll, taxes, and interest of 3.55 M. | |
| Tanvex BioPharma has accumulated about 1.65 B in cash with (1.39 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.29. | |
| Roughly 54.0% of the company shares are owned by insiders or employees |
Additional Tools for Tanvex Stock Analysis
When running Tanvex BioPharma's price analysis, check to measure Tanvex BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tanvex BioPharma is operating at the current time. Most of Tanvex BioPharma's value examination focuses on studying past and present price action to predict the probability of Tanvex BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tanvex BioPharma's price. Additionally, you may evaluate how the addition of Tanvex BioPharma to your portfolios can decrease your overall portfolio volatility.